In an era of increased focus on precision medicine, tumour-agnostic therapies have emerged as a revolutionary new approach to cancer treatment. Tumour-agnostic therapies target specific genomic anomalies or molecular features regardless of tumour site of origin. Pan-tumour approaches signal an important new paradigm in clinical management, whereby tumour genomic signature supersedes histology in informing treatment decisions. In recent years, tumour-agnostic therapies have become a key focus area for an increasing number of small and large pharmaceutical companies.

Enjoying our latest content?
Log in or create an account to continue

  • Access the most recent journalism from Nature's award-winning team
  • Explore the latest features & opinion covering groundbreaking research
Access through your institution

or

Sign in or create an account
Continue with Google
Continue with ORCiD